Abstract
The most accepted and least biased manner to demonstrate clinical benefit for any new treatment is to show that it conveys a survival advantage in a well-designed phase III, randomized clinical trial. However, in selected cases, an exception can be made to this sound rule. This review aims at elucidating one such example. In particular, I intend to show that when an individualized form of immunotherapy like idiotypic vaccination, which by definition is completely inactive against any tumor cells, is applied to cancer patients with indolent follicular lymphoma, a carefully crafted phase II clinical trial may be able to demonstrate clinical benefit better and more rapidly than a phase III alternative. This consideration might be rather important over the next two to three years, since the results of as many as three ongoing phase III clinical trials on idiotype vaccines are expected to be unveiled within this time frame, following the release of conclusive data of our phase II clinical trial, which is imminent.
Keywords: immunoglobulin, cell-mediated cytotoxicity (ADCC), T lymphocytes (CTLs), chemotherapy, phase II clinical trials, transfectants
Reviews on Recent Clinical Trials
Title: Clinical Benefit of Idiotype Vaccines: Too Many Trials for a Clever Demonstration?
Volume: 1 Issue: 1
Author(s): Maurizio Bendandi
Affiliation:
Keywords: immunoglobulin, cell-mediated cytotoxicity (ADCC), T lymphocytes (CTLs), chemotherapy, phase II clinical trials, transfectants
Abstract: The most accepted and least biased manner to demonstrate clinical benefit for any new treatment is to show that it conveys a survival advantage in a well-designed phase III, randomized clinical trial. However, in selected cases, an exception can be made to this sound rule. This review aims at elucidating one such example. In particular, I intend to show that when an individualized form of immunotherapy like idiotypic vaccination, which by definition is completely inactive against any tumor cells, is applied to cancer patients with indolent follicular lymphoma, a carefully crafted phase II clinical trial may be able to demonstrate clinical benefit better and more rapidly than a phase III alternative. This consideration might be rather important over the next two to three years, since the results of as many as three ongoing phase III clinical trials on idiotype vaccines are expected to be unveiled within this time frame, following the release of conclusive data of our phase II clinical trial, which is imminent.
Export Options
About this article
Cite this article as:
Bendandi Maurizio, Clinical Benefit of Idiotype Vaccines: Too Many Trials for a Clever Demonstration?, Reviews on Recent Clinical Trials 2006; 1 (1) . https://dx.doi.org/10.2174/157488706775246120
DOI https://dx.doi.org/10.2174/157488706775246120 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
On the Origin of Epidermal Cancers
Current Molecular Medicine Therapeutic Targeting of Apoptotic Pathways in Cancer
Current Drug Targets Smart Stimuli Sensitive Nanogels in Cancer Drug Delivery and Imaging: A Review
Current Pharmaceutical Design Phosphoinositide 3-Kinases and Leukocyte Migration
Current Immunology Reviews (Discontinued) The Proteins Interacting with Prmt5 in Medaka (Oryzias latipes) Identified by Yeast Two-Hybridization
Protein & Peptide Letters MATra - Magnet Assisted Transfection: Combining Nanotechnology and Magnetic Forces to Improve Intracellular Delivery of Nucleic Acids
Current Pharmaceutical Biotechnology Application of Sugar-Base Anhydro Bridge for Modification of Nucleosides in the 2’- and/or 3’-Positions - Revisited
Current Organic Chemistry Cytotoxic, Apoptotic and DNA Synthesis Inhibitory Effects of Some Thiazole Derivatives
Letters in Drug Design & Discovery Hepatic MicroRNA Orchestra: A New Diagnostic, Prognostic and Theranostic Tool for Hepatocarcinogenesis
Mini-Reviews in Medicinal Chemistry Gene Transfer and Drug Delivery with Electric Pulse Generators
Current Drug Metabolism Strong Anti-tumorous Potential of Nardostachys jatamansi Rhizome Extract on Glioblastoma and In Silico Analysis of its Molecular Drug Targets
Current Cancer Drug Targets How Do Microtubule-Targeted Drugs Work? An Overview
Current Cancer Drug Targets Quantitative Structure-Activity Relationship Studies: Understanding the Mechanism of Tyrosine Kinase Inhibition
Current Enzyme Inhibition Benzimidazoles: An Ideal Privileged Drug Scaffold for the Design of Multitargeted Anti-inflammatory Ligands
Mini-Reviews in Medicinal Chemistry Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy
Current Topics in Medicinal Chemistry Recent Developments on the Role of Mitochondria in Poly(ADP-ribose) Polymerase Inhibition
Current Medicinal Chemistry Non Polymeric Nanoparticles for Photodynamic Therapy Applications: Recent Developments
Current Medicinal Chemistry Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor
Combinatorial Chemistry & High Throughput Screening Dry Eyes in Rheumatic Disease
Current Rheumatology Reviews The Chemistry and Pharmacology of Genistein
The Natural Products Journal